Product image of Kolistimetatnatrium Noridem (Colistimethate Sodium) supplied by GNH India

Kolistimetatnatrium Noridem

Active Ingredient:
Colistimethate Sodium
Origin:
EU

Kolistimetatnatrium Noridem (Colistimethate Sodium)

Colistimethate Sodium, the active ingredient in Kolistimetatnatrium Noridem, is a Polymyxin antibiotic presented as an inhalation solution for inhalation use. It is employed to treat chronic Pseudomonas aeruginosa lung infection in patients with cystic fibrosis and related chronic respiratory conditions. The product complies with EU pharmaceutical standards and is formulated for nebulised delivery to the lower airways.

GNH India supplies Kolistimetatnatrium Noridem as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Manufacturer / TM Owner

Noridem Enterprises Ltd

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Kolistimetatnatrium Noridem is a Polymyxin antibiotic used to manage chronic Pseudomonas aeruginosa infections in the respiratory tract.

  • Cystic fibrosis: reduces bacterial load and improves lung function in patients with chronic Pseudomonas infection.
  • Non‑cystic fibrosis bronchiectasis: helps control persistent Pseudomonas colonisation and decreases exacerbation frequency.
  • Chronic Pseudomonas aeruginosa lung infection: supports airway clearance and reduces the risk of acute worsening.

How It Works

  • Colistimethate Sodium is hydrolysed to colistin, which binds to the lipopolysaccharide component of the outer membrane of Gram‑negative bacteria. This interaction displaces calcium and magnesium ions, destabilising the membrane, increasing its permeability, and ultimately causing bacterial cell death. The drug’s activity is concentration‑dependent and primarily affects Pseudomonas aeruginosa strains in the pulmonary environment.

Side Effects

Adverse reactions may occur with inhaled colistimethate sodium. Monitoring for respiratory and systemic effects is recommended.

Common Side Effects

  • Cough: mild to moderate irritation of the airways.
  • Bronchospasm: transient narrowing of the bronchial passages.
  • Throat irritation: discomfort or soreness in the throat.
  • Nausea: occasional gastrointestinal upset.
  • Dysgeusia: altered taste sensation.
  • Headache: mild to moderate intensity.

Serious or Rare Side Effects

  • Respiratory distress: severe bronchospasm or hypoxia.
  • Allergic reaction: rash, urticaria, or anaphylaxis.
  • Nephrotoxicity: impaired kidney function, especially with systemic absorption.
  • Neurotoxicity: paresthesia, dizziness, or seizures.
  • Hemoptysis: coughing up blood.
  • Elevated liver enzymes: signs of hepatic involvement.

Precautions & Warnings

Use of inhaled colistimethate sodium requires careful patient assessment and monitoring.

  • Renal function: assess baseline kidney status and monitor periodically.
  • Hepatic function: evaluate liver enzymes before initiating therapy.
  • Respiratory status: ensure patient can tolerate nebulised administration; monitor for bronchospasm.
  • Pregnancy and lactation: avoid use unless potential benefit justifies potential risk.
  • Concomitant nephrotoxic drugs: avoid or adjust dosing when used together.
  • Store below 25°C: keep in original container, protect from light and moisture.

Avoid Interactions

Colistimethate sodium may interact with other medications, influencing safety or efficacy.

Major Interactions (Avoid)

  • Nephrotoxic agents (e.g., aminoglycosides, vancomycin): combined use may increase risk of kidney injury.
  • Neuromuscular blockers (e.g., curare): may potentiate neuromuscular weakness.

Moderate Interactions (Monitor Closely)

  • Loop diuretics: may enhance renal effects; monitor electrolytes.
  • Other inhaled antibiotics: assess cumulative respiratory irritation.
  • CYP450 substrates: colistin is not a major CYP inhibitor, but monitor for unexpected changes.

Frequently Asked Questions

Kolistimetatnatrium Noridem is an inhaled formulation of colistimethate sodium indicated for the treatment of chronic Pseudomonas aeruginosa lung infection, primarily in patients with cystic fibrosis or other chronic respiratory conditions where the bacteria persist despite other therapies.

After inhalation, colistimethate sodium is converted to colistin, which binds to the lipopolysaccharide layer of Gram‑negative bacterial membranes. This binding disrupts membrane integrity, leading to increased permeability, leakage of cellular contents, and bacterial cell death, effectively reducing the bacterial burden in the lungs.

The prescribed dose of Kolistimetatnatrium Noridem is determined by the treating physician based on the patient’s age, weight, severity of infection, and renal function. The healthcare professional will specify the exact volume and frequency for nebulised administration.

The safety of inhaled colistimethate sodium in pregnancy or while breastfeeding has not been established. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Kolistimetatnatrium Noridem (colistimethate sodium) belongs to the polymyxin class and is particularly effective against multidrug‑resistant Pseudomonas aeruginosa. Compared with inhaled tobramycin, it offers a different mechanism of action and may be used when resistance to aminoglycosides is present, though both require careful monitoring for respiratory side effects.

The inhalation solution should be stored below 25 °C, in its original packaging, protected from light and moisture. Do not freeze the product. Before use, inspect the vial for particulate matter or discoloration and follow aseptic techniques when preparing the nebuliser solution.

The medication is supplied as a sterile solution for nebulisation. Patients use a compatible nebuliser device, adding the prescribed volume to the nebuliser cup, and inhale the aerosolized drug for the duration recommended by the prescriber, typically ranging from 10 to 30 minutes per session.

Serious adverse events include severe bronchospasm, respiratory distress, allergic reactions such as anaphylaxis, nephrotoxicity due to systemic absorption, and neurotoxicity manifesting as dizziness, paresthesia, or seizures. Prompt medical attention is required if any of these symptoms develop.

Patients with known hypersensitivity to colistimethate sodium or any component of the formulation should avoid its use. Additionally, individuals with severe renal impairment, uncontrolled asthma, or those receiving concurrent nephrotoxic or neuromuscular‑blocking agents should be evaluated carefully before initiating therapy.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Colistimethate Sodium

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT